dihexa
COGNITIVE · ANGIOTENSIN IV ANALOGUE · MODIFIED TRIPEPTIDE
also: PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa is a small, orally bioavailable angiotensin IV analogue developed at Washington State University and reported to enhance hepatocyte growth factor signalling through the c-Met receptor, with rodent studies describing marked dendritic spine formation. Its core supporting literature has since been retracted, no human trial has ever been conducted, and the mechanism it claims is a well-established cancer proliferation pathway.
// our evidence grade — unedited
Both foundational papers establishing Dihexa's mechanism and procognitive effects were retracted by the Journal of Pharmacology and Experimental Therapeutics in 2025 following image-manipulation findings, leaving a compound with zero human trials and an oncogenic mechanism resting on withdrawn evidence.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide |
| cas | 1401708-83-5 |
| formula | C27H44N4O5 |
| molar mass | 504.7 g/mol |
| purity | ≥ 98% HPLC |
| form | lyophilised powder, sealed vial |
| storage | Lyophilised powder stable at -20°C protected from light and moisture; reconstituted solutions should be held at 2-8°C for short-term use or aliquoted at -20°C, avoiding repeated freeze-thaw cycles. |
| solubility | Poorly water-soluble; laboratory preparations typically use DMSO as primary solvent, sometimes with subsequent dilution into aqueous buffer. |
| sequence | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide (modified tripeptide, not a standard peptide sequence) |
// select size
crypto payment · research use only · not for human consumption
// others in Cognitive